Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
Asengeprast by Certa Therapeutics for Systemic Sclerosis (Scleroderma): Likelihood of Approval
Asengeprast is under clinical development by Certa Therapeutics and currently in Phase II for Systemic Sclerosis (Scleroderma). According to GlobalData,...